No Correlation Between Increasing Drug Prices and Manufacturing Rebates in Major Drug Categories

No Correlation Between Increasing Drug Prices and Manufacturing Rebates in Major Drug Categories

A new market analysis contradicts claims that drug pricing is contingent on the level of rebates and discounts manufacturers negotiate with PBMs.

Major findings:
Higher-than-average price increases in drug categories where manufacturers negotiate low rebates; Lower-than-average price increases in drug categories where manufacturers negotiate high rebates; Prices increasing regardless of rebate levels.